Kornimate/medical-research-clean huggingface dataset:
reiki effects on heart rhythm, biochemistry and cortisol findings, and anxiety

Conditions: Anxiety; Heart Diseases

Summary: this study aimed to investigate the effects of reiki, which is a complementary and traditional method, on heart rhythm, biochemistry and cortisol findings, and anxiety in individuals with arrhythmia.

reiki has an essential place in modern medicine and the nursing profession because it cures many diseases resistant to known treatments, has no side effects, is easy to apply, and is safe, effective, and economical. in the reiki method, the energy is transferred through the hands, and a care provider nurse is a tool that performs their profession by touching in patient care and also shares the universal life energy, transferring the flowing and formed energy. when the literature is reviewed, there are a limited number of studies in which reiki affects heart rate, cortisol level, and vital signs. however, there are not enough studies examining the effects of heart patients' symptoms, anxiety, and their condition on reiki results. in this context, this study aimed to investigate the effects of reiki energy on heart rhythm, biochemistry, cortisol findings, and anxiety in people with arrhythmia. the study was conducted as a pretest-posttest, randomized prospective, single-blind and placebo-controlled. the study was conducted with patients who applied to a training and research hospital with arrhythmia complaints between april 5 and june 30, 2022. the data was collected using "personal information form (pif)" and "beck anxiety scale (bas)". also, biochemical tests and cortisol findings and ecg (electrocardiography) analyses were assessed. pif and bas were applied to patients who agreed to participate in the study and met the inclusion criteria. then blood was drawn for biochemical tests and cortisol findings and ekg was taken. patients were randomized 1:1 into groups by a single therapist at a single institution according to a parallel design. there were three treatment arms in the study: reiki treatment (n=22), sham reiki treatment (placebo)(n=22), and a control group with no treatment (n=22). a second-degree reiki practitioner applied reiki to the energy centers for 30 minutes in the reiki group. on the second day, distant reiki was also conducted for 30 minutes. the sham reiki group, on the other hand, was handled similarly to the reiki practice by a student who had not been trained in reiki. in the control group, nothing was done. one week later, bas was applied to all patients, blood was drawn for biochemical testing and an ecg was recorded.

Eligibility criteria:
inclusion criteria: * age 18 and over * no communication problem * diagnosed with cardiac arrhythmia * who agree to participate in the reiki practice * who is competent to answer the data collection tools to be used in the research * patients who have not used complementary practices in the last six months exclusion criteria: * reiki practitioner or trainer, * have received energy therapies such as reiki/therapeutic touch, * patients who were diagnosed with another disease during the research process.

Keywords: reiki heart rhythm arrythmia anxiety
characterization of aortic tissue at reoperation

Conditions: Aortic Aneurysm; Aortic Dissection

Summary: this study will analyse factors contributing to cardiac re-operation to determine causative effects

this study will collect clinical data on the characteristics of aortic tissue on which bioglue has been applied during a previous cardiovascular surgery. this is a post market surveillance study.

Eligibility criteria:
inclusion criteria: * subjects undergoing an aortic re-operation * subject has had bioglue used during previous aortic surgery * subject is willing and able to give written informed consent for participation exclusion criteria: * subject with a history of vasculitis * subject with active infection (endocarditis) * subject with a history of chronic inflammatory condition which may have led to ongoing tissue damage * subject with a history of auto immune disease
a placebo- and paroxetine-controlled study of the efficacy, safety and tolerability of agomelatine (25 or 50 mg) in the treatment of major depressive disorder (mdd)

Conditions: Major Depressive Disorder

Summary: this study will evaluate the efficacy, safety and tolerability of agomelatine 25 mg or 50 mg per day and will compare agomelatine and paroxetine tolerability. eligible patients will receive double-blind study medication for 8 weeks. one week after completion of the double-blind treatment phase there will be a single follow-up visit.


Eligibility criteria:
inclusion criteria: * male and female adults, 18 through 70 years of age, inclusive * diagnosis of major depressive disorder according to dsm-iv criteria * ham-d17 total score \> or = 22 at screening and baseline exclusion criteria: * history of non-response to paroxetine * patients who have been previously treated with agomelatine * history of bipolar disorder (i or ii), schizophrenia, schizoaffective disorder, eating disorder, or obsessive compulsive disorder * any current axis i disorder other than major depressive disorder which is the focus of treatment * substance or alcohol abuse in the last 30 days, dependence in the last 6 months * use of any psychoactive medication after the screening visit * female patients of childbearing potential who are not using effective contraception other protocol-defined inclusion/exclusion criteria may apply

Keywords: agomelatine, major depressive disorder, mdd, depression
effects of transcutaneous vagal nerve stimulation on hemodynamics parameters

Conditions: Hypertension

Summary: the vagal stimulation is a promising therapy for a lot of disorders as well as hemodynamic regulatory way. in order to minimize the harm of a surgery chip implantation, actually it was developing a non-invasive device that is able to stimulate the auricular branch of vagal nerve. it has been shown that trans-auricular vagal stimulation (tvns) causes direct stimulation of the vagal nerve. however, there are still no strong evidences about it actions regarding the autonomic modulation. the aim of this study is to evaluate effects of tvns on heart rate, blood pressure and the autonomic control in healthy and hypertensive subjects, at rest and after orthostatic position


Eligibility criteria:
normotensive group inclusion criteria: * healthy volunteers * sign the consent term normotensive group exclusion criteria: * smokers * alcoholism * drug treatment * skin lesion in the ear region * chronic or acute diseases * pregnancy * be participating in another research protocol * high performance athletes * recent surgery * vaso-vagal syndrome hypertensive group inclusion criteria: * hypertensive diagnosis (with or without anti-hypertensive drugs treatment) or * ambulatory blood pressure monitoring (abpm) \>130/85 * sign the consent term hypertensive group exclusion criteria: * smokers * alcoholism * beta-blockers treatment * skin lesion in the ear region * associated diseases * pregnancy * be participating in another research protocol * high performance athletes * recent surgery * vaso-vagal syndrome

Keywords: autonomic control transcutaneous vagal nerve stimulation transauricular vagal nerve stimulation
prevalence and impact in work productivity of gastroesophageal reflux disease (gerd) in primary care patients with upper gastrointestinal (gi) symptoms using gerdq

Conditions: Gastroesophageal Reflux Disease

Summary: the purpose of the study is to provide data on the gerd prevalence as percentage of patients with upper gi symptoms that are identified with gerd using the gerdq questionnaire. furthermore the study aims to estimate gerd prevalence in patients based on their symptoms as they respond to a physician's questionnaire, to observe possible variations between the two methods (physicians' symptom rating and gerdq), to objectively measure treatment response and to identify the percentage of patients that may require alterations of their treatment. finally, to describe the impact of gerd symptoms on work productivity.


Eligibility criteria:
inclusion criteria: * patients with upper-gi symptoms the last week prior visiting the investigator exclusion criteria: * history of oesophageal, gastric or duodenal surgery * treatment with nsaids/acetylsalicylic acid within the last week prior to the study visit * ppi use for healing of nsaids induced ulcer or for hp eradication

Keywords: gerd gerdq questionnaire work productivity greece
changes in cerebral oxygenation during laparoscopic pyloromyotomy

Conditions: Pyloric Stenosis

Summary: a prospective study that will assess the effect of laparoscopy on tissue oxygenation in the patients undergoing a laparoscopic pyloromyotomy at nationwide children's hospital. tissue oxygenation will be assessed non-invasively using near infrared spectroscopy, a device that is commonly used in our operating rooms to assess cerebral and tissue oxygenation.

this prospective study will include 50 patients under the age of 18 years who are having laparoscopic pyloromyotomy. there will be no change in the anesthetic or perioperative care of these patients. tissue and cerebral oxygenation will be monitored using near infrared spectroscopy (nirs). prior to anesthetic induction, the nirs monitor will be placed on the forehead. the device is non-invasive like pulse oximetry using a non-painful adhesive sticker. the device can be applied to different sites on the body to measure cerebral, tissue or even organ oxygenation. for the purpose of the study, the investigators will place one monitor on the forehead to measure tissue oxygenation and a second over the lower back to measure tissue (muscle or renal) oxygenation. these devices are used routinely in the operating room and the cardiothoracic intensive care unit for cardiac patients. although not used on every surgical procedure, nirs monitoring can be used on all patients who are undergoing major surgical procedures. tissue and cerebral oxygenation will be recorded continuously starting just prior to anesthetic induction until the completion of the procedure.

Eligibility criteria:
inclusion criteria: * children at nationwide children's hospital under the age of 18 years who are having laparoscopic pyloromyotomy exclusion criteria: * none
topical dhea against vaginal atrophy

Conditions: Vaginal Atrophy

Summary: the purpose of this study is to determine the dose-response of vaginal mucosa parameters to the local action of dhea (dehydroepiandrosterone) in postmenopausal women suffering from vaginal atrophy.


Eligibility criteria:
inclusion criteria: * postmenopausal women (non hysterectomized or hysterectomized) * women between 40 and 75 years of age * willing to participate in the study and sign an informed consent * women having a low maturation index (no greater part of guidance than 5% of superficial cells on vaginal smear) * women having a vaginal ph above 5 * women who have self-identified at least one moderate to severe symptoms of vulvovaginal atrophy exclusion criteria: * undiagnosed abnormal genital bleeding * hypertension equal to or above 160/95 mm hg or not controlled by standard therapy * the administration of any investigational drug within 30 days of screening visit * endometrial hyperplasia at biopsy performed at screening or endometrial cancer * use of estrogens/progestins products (vaginal, oral, pellet, transdermal, etc) in the 4 weeks to 6 months (depending on the product used) prior study entry

Keywords: vulvar/vaginal atrophy atrophic vaginitis dehydroepiandrosterone dhea prasterone vaginorm menopause intrarosa
colchicine for the treatment of osteoarthritis of the knee

Conditions: Osteoarthritis; Osteo Arthritis Knee

Summary: this prospective, double-blinded, placebo-controlled, randomized trial will enroll 120 skoa subjects at the nyu center for musculoskeletal care. patients meeting entry criteria will be randomized 1:1 to treatment with colchicine or placebo daily for 3 months. subjects will have detailed evaluation of standardized clinical pain outcomes, candidate peripheral blood biomarkers, baseline knee radiographs as well as msk-us, and a subset will undergo evaluation of their synovial fluid.


Eligibility criteria:
inclusion criteria: * are 40 years old or older * continue to experience frequent knee symptoms as defined above * have kl grade 2 or 3 on their last knee radiograph done for the parent study * have an estimated glomerular filtration rate (egfr) \> 30 ml/min (mdrd equation) and liver transaminases \< 2x the upper limit of normal * have a bmi ≤ 32 at the time of enrollment * agree to be randomized to take colchicine or placebo daily for 3 months exclusion criteria: * have received hyaluronic acid or corticosteroid steroid injection within the past 3 months * have a diagnosis of gout/pseudogout or other inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy etc). * have a diagnosis of diabetes mellitus, chronic infectious disease, congestive heart failure, non-cutaneous cancer within the past 5 years * plan on undergoing total knee replacement within the next 3 months * be using any medication that is a strong cyp3a4 inhibitor whose metabolism may interact with colchicine (e.g., certain protease inhibitors, certain azole antifungal agents, clarithromycin).
bone graft necessity in opening-wedge high tibial osteotomy

Conditions: Osteoarthritis

Summary: the purpose of this study is to determine wether autologous bone graft from iliac crest enhances bone union of tibial osteotomies, in the treatment of varus knee deformity.

opening-wedge high tibial osteotomy is a classic procedure,but the use of autologous bone graft from iliac crest causes pain and bleeding. bone union occur even without bone graft, but no clinical trials compared results of the twoo procedures.

Eligibility criteria:
inclusion criteria: * varus knee deformity * unicompartmental arthrosis exclusion criteria: * patellar arthrosis * lateral arthrosis * inflammatory diseases * bone healing impair drugs or diseases

Keywords: osteotomy knee varus deformity bone graft
back and neck pain in adolescence

Conditions: Back Pain

Summary: to validate the german version of the young spine questionnaire (g-ysq) and to study back and neck pain in adolescents between 10 and 16 years during one year by means of g-ysq.

in two settings (school, clinics) back and neck pain of 10 to 16 years old adolescents will be assessed by the german version of the young spine questionnaire at 6 points in time during one year. validity, reliability and responsiveness of the g-ysq will be determined and the development of back and neck pain within a year will be described.

Eligibility criteria:
inclusion criteria: * 10 to 16 years old exclusion criteria: * younger than 10, older than 16
correlation of pet-ct studies with serum protein analysis

Conditions: Carcinomas (Including Squamous Cell and Adenocarcinoma)

Summary: to correlate serum proteomics patterns with pet/ct findings to improve cancer diagnosis, staging, prognosis, and therapy monitoring.


Eligibility criteria:
inclusion criteria:1. patients must have a pet/ct study performed at the time of blood collection. 2. patients must understand and voluntarily sign an informed consent form after the contents have been fully explained to them. exclusion criteria:1. patients who are not eligible for a pet/ct study.
outcome of glargine insulin in renal impairment patients with diabetic ketoacidosis

Conditions: Chronic Kidney Diseases

Summary: the study aims to compare between the use of continuous low dose insulin infusion versus co-administration of low dose continuous insulin infusion and early subcutaneous insulin glargine in diabetic ketoacidosis patients with chronic renal impairment. aim to investigate the effect of using the long acting insulin analogue glargine on the resolution time of diabetic ketoacidosis in renal impairment patients who have altered insulin pharmacokinetics and pharmacodynamics and the rate of adverse effects of this approach

diabetic ketoacidosis (dka) is one of the most common and grave acute complications of diabetes and is a significant cause of morbidity and mortality. the current available guidelines state that the most effective means of insulin delivery during dka is a continuous low dose infusion of regular insulin. the patients must be admitted to the icu for frequent and close monitoring .in addition to insulin infusion, correction of dehydration, and electrolyte and acid base disorders is achieved together with identification and treatment of co-morbid precipitating factors . "the joint british diabetes societies guideline for the management of diabetic ketoacidosis" recommends continuation of a long-acting insulin analogue such as insulin glargine during the initial management of dka because it provides background insulin when the intravenous insulin is discontinue. administering basal insulin concomitantly with regular insulin infusion was found to be well tolerated, associated with faster resolution of acidosis without any adverse effects; patients required a shorter duration of intravenous insulin infusion and had a lower total dose of intravenous insulin and significantly decreased hyperglycemia after discontinuation of the intravenous insulin .

Eligibility criteria:
inclusion criteria: * male and female patients. * type i and type ii diabetes mellitus. * patients on insulin and/or oral hypoglycemic therapy. * duration of diabetes more than 5 years. * medical and surgical patients. exclusion criteria: * severe persistent hypotension (sbp \<80 inspite of receiving 1000ml of normal saline). * acute myocardial infarction. * progressive renal failure or end stage renal disease defined as egfr \< 15ml/min. * liver cell failure. * pregnancy. * need for emergency surgery
a phase 1, open-label study of latanoprost acid plasma concentrations in pediatric and adult glaucoma patients treated with latanoprost.

Conditions: Glaucoma; Ocular Hypertension

Summary: to evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.

pharmacokinetics and safety

Eligibility criteria:
inclusion criteria: * this study will enroll pediatric and adult subjects with glaucoma or ocular hypertension receiving treatment with latanoprost in either one or both eyes for at least two weeks. * the pediatric subjects will be grouped by age (0 to \<3 years, 3 to \<12 years, 12 to 18 years). exclusion criteria: * ocular inflammation/infection or a history of ocular inflammation/infection within 3 months prior to the screening visit. * history of ocular trauma or surgery in either eye within 14-days of the screening visit. * use of continuous wear contact lenses.

Keywords: latanoprost pediatrics pharmacokinetics safety
platelet-rich plasma (prp) in reconstructive surgery on children with retractable burn sequelae on extremities

Conditions: Burns

Summary: does the addition of platelet-rich plasma (prp) to release of burn contractures and skin graft on the limbs of children with retractable burn sequelae reduce the initial time of the compressive treatment and maintain or lower the graft's retraction?

hypothesis: 1. the use of prp will allow to initiate sooner the compressive treatment during the post graft surgery evolution, in fewer days on average than the traditional method (18 ds). 2. the use of prp will maintain the same initial size of the graft. the study's domain corresponds to burn sequelae on children in treatment with reconstructive surgery due to retractile sequelae located on their upper and lower limbs, with functional compromise during their growth process. one of the treatments used for this problem is the surgical technique of with release of burn contractures and skin graft. split skin grafts are at risk of suboptimal "take" due to bleeding and infection which would, on the one hand, delay the initiation of the rehabilitation with preventive compression to avoid the retraction of the grafted area. 20% of the children that arrive in coaniquem (approximately 7,000 annually), require rehabilitation. of these, 32% have surgery and 9% of those are release of burn contractures and skin graft mainly on extremities.

Eligibility criteria:
inclusion criteria: * patients with burn sequelae on their upper or lower limbs * treated with release of burn contractures and skin graft on their upper or lower limbs * between 5 and 21 years old * following instructions in their homes * with informed and written consent * weight 35 kg or more * blood count * hepatic and coagulation tests * paediatric evaluation prior to surgery exclusion criteria: * background of blood alterations * another current pathology

Keywords: burn sequelae prp children
comparison of scs and pmr in patients with refractory angina pectoris

Conditions: Angina Pectoris

Summary: randomised trial of spinal cord stimulation (scs) and percutaneous myocardial laser revascularisation (pmr) in patients with refractory angina pectoris. hypothesis: difference in exercise tolerance at 12 months between scs and pmr

the purpose of this open, parallel, single-center prospective, randomised controlled trial is to compare two treatments: spinal cord stimulation (scs) and percutaneous myocardial laser revascularisation (pmr) and assess their use and longer term effect in patients with refractory angina pectoris.

Eligibility criteria:
inclusion criteria: * patient limiting angina (ccs iii or iv) despite maximally tolerated medical therapy * documented coronary artery disease (within the last 9 months prior baseline), which is unsuitable for conventional revascularisation techniques * patient has documented reversible ischemia on nuclear scan (tc-99 sestamibi) * patient is limited in daily activities, primarily exercice capability, by their angina pain * age 18 or older * patient must understand the therapy and give informed consent * patient must be available for appropriate follow-up times for length of study * non pregnant woman exclusion criteria: * not candidate for surgical implantation of scs and/or not for pmr and/or unable to use scs device appropriately for treatment * patient who has had one or more major cardiac events within 2 months * patient with myocardial wall thickness\< 8 mm in the ischaemic area to be treated as verified by echocardiography * patient with extensive peripheral vascular disease that precludes vascular access required for pmr * patient on intravenous therapy to control their symptoms * patient who is unlikely to survive for more than 12 months due to non cardiac condition e.g.malignancy * patient who has other diseases that are considered of greater clinical significance than the angina pectoris that would impact the ability of the clinician to adequately assess the incremental effects of the trial treatment * patient with ejection fraction of less than 30 % as verified by echocardiography * patient with cause of angina other than coronary artery disease (e.g. syndrome "x" patient) * patient who are unable to perform treadmill exercice test per protocol * patient who was previously enrolled in this study, or is currently in another clinical study, which will interfere with this protocol * patient who has has scs , a tmlr or pmr procedure in the past * patient with an implanted pacemaker or defibrillator * patient who has medical conditions which may require magnetic resonance imaging (mri) * patient with history of dementia or other persisting mental disorders significantly interfering with ability to cooperate or comply with the requirements of the study or comprehend informed consent * patient with history of alcohol og drug abuse

Keywords: angina pectoris spinal cord stimulation (scs) percutaneous myocardial revascularisation (pmr) refractory angina pectoris